5-溴乙酰-3-异苯唑 | 14731-14-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 5-溴乙酰-3-异苯唑
• 中文别名: 2-溴-1-(3-苯基异噻唑-5-基)乙酮；2-溴-1-(3-苯基异唑-5-基)乙烷-1-酮；2-溴-1-(3-苯基异恶唑)乙基-1-酮；5-(溴乙酰基)-3-苯基异噁唑
• 英文名称: 2-bromo-1-(3-phenylisoxazol-5-yl)ethan-1-one
• 英文别名: 2-bromo-1-(3-phenyl-1,2-oxazole-5-yl)ethan-1-one；2-bromo-1-(3-phenylisoxazol-5-yl)-ethanone；2-bromo-1-(3-phenylisoxazol-5-yl)ethanone；5-(bromoacetyl)-3-phenyl isoxazole；2-bromo-1-(3-phenyl-isoxazol-5-yl)-ethanone；5-(bromoacetyl)-3-phenylisoxazole；2-bromo-1-(3-phenyl-1,2-oxazol-5-yl)ethanone
• CAS: 14731-14-7
• 化学式: C₁₁H₈BrNO₂
• 分子量: 266.094
• InChiKey: XTBXGZOVSCTNEC-UHFFFAOYSA-N

物化性质

• 熔点：
  109 °C
• 沸点：
  416.8±35.0 °C(Predicted)
• 密度：
  1.516±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090

SDS

Name:	2-Bromo-1-(3-phenylisoxazol-5-yl)ethan-1-one 95+% Material Safety Data Sheet
Synonym:	5-(Bromoacetyl)-3-phenylisoxazol
CAS:	14731-14-7

Section 1 - Chemical Product MSDS Name:2-Bromo-1-(3-phenylisoxazol-5-yl)ethan-1-one 95+% Material Safety Data Sheet
Synonym:5-(Bromoacetyl)-3-phenylisoxazol

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
14731-14-7	2-Bromo-1-(3-phenylisoxazol-5-yl)ethan	95+%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 14731-14-7: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 110 - 113 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H8BrNO2
Molecular Weight: 266

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, reducing agents, bases, amines, halogenated agents, halogens.
Hazardous Decomposition Products:
Hydrogen cyanide, nitrogen oxides, carbon monoxide, carbon dioxide, hydrogen bromide, bromine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 14731-14-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Bromo-1-(3-phenylisoxazol-5-yl)ethan-1-one - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/39 Wear suitable protective clothing and
eye/face protection.
WGK (Water Danger/Protection)
CAS# 14731-14-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 14731-14-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 14731-14-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴乙酰-3-异苯唑 在 水 、 三苯基锑 作用下， 反应 0.17h， 以63%的产率得到1-(3-苯基异噁唑-5-基)乙酮
  参考文献：
  名称：

  微波辅助的水中三芳基苯乙烯类化合物对α-溴酮的脱溴作用。

  摘要：

  在水中微波照射下，几种α-溴芳基酮与三芳基stibanes反应，得到相应的脱溴酮。在相似的反应条件下，在水中1,2-消除vic-二溴化物提供相应的E-烯烃。该反应是用于水中有机转化的有机锑化合物的第一个例子。

  DOI：

  10.1248/cpb.c17-00533
• 作为产物：
  描述：

  5-acetyl-4,5-dihydro-3-phenylisoxazole 在 溴 作用下， 以 二氯甲烷 为溶剂， 反应 3.5h， 生成 5-溴乙酰-3-异苯唑
  参考文献：
  名称：

  In search of new chemical entities with spermicidal and anti-HIV activities

  摘要：

  Several compounds belonging to 2-isoxazolines (4,5a-c), isoxazoles (3,6a-c) and 1-amino-1-cycloalkyl-2-substituted phenyl ethanes (16-18,a-e) have been synthesised and found to possess spermicidal activity. Out of these a couple of compounds (5a and 6a) exhibit anti-HIV activity. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(99)00188-1

文献信息

• DPP IV inhibitors
  申请人：——

  公开号：US20030130281A1

  公开（公告）日：2003-07-10

  The present invention relates to compounds of formula (I) 1 wherein R 1 , R 2 , and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.

  本发明涉及以下式（I）的化合物： 其中R1、R2和X如描述和权利要求中所定义，并且其药学上可接受的盐。这些化合物可用于治疗和/或预防与DPP IV相关的疾病，如糖尿病，特别是非胰岛素依赖型糖尿病和糖耐量受损。
• 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
  申请人：Dickson K. John

  公开号：US20060052416A1

  公开（公告）日：2006-03-09

  2-Amido-4-substituted-aryl-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, methods of using compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions comprising compounds exhibiting ATP-utilizing enzyme inhibitory activity, are disclosed.

  基于2-氨基-4-取代芳基噻唑的化合物展现出ATP利用酶抑制活性，公开了利用展现出ATP利用酶抑制活性的化合物的方法，以及包含展现出ATP利用酶抑制活性的化合物的组合物。
• OPIOID RECEPTOR MODULATORS AND USE THEREOF
  申请人：National Health Research Institutes

  公开号：US20170056377A1

  公开（公告）日：2017-03-02

  Disclosed is an in vitro screening method for identifying an antagonist-to-agonist allosteric modifier of a mu-opioid receptor and an in vivo method for confirming that a test compound is such a modifier of a mu-opioid receptor. Also disclosed is a method for treating an opioid receptor-associated condition using a compound of Formula (I) and a pharmaceutical composition containing the same.

  揭示了一种体外筛选方法，用于识别μ-阿片受体的拮抗剂-激动剂异位调节剂，并揭示了一种体内方法，用于确认测试化合物是否为μ-阿片受体的这种调节剂。还揭示了一种使用式（I）化合物和含有该化合物的药物组合物治疗阿片受体相关疾病的方法。
• [EN] 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS<br/>[FR] DERIVES DE 1-(2H-PYRAZOL-3-YL)-3-{4-`1-(BENZOYL)-PIPERIDIN-4-YLMETHYL!-PHENYL}-UREE ET COMPOSES ASSOCIES UTILISES COMME INHIBITEURS DE LA KINASE P38 ET/OU COMME INHIBITEURS DU FACTEUR DE NECROSE TUMORALE (TNF) DANS LE TRAITEMENT DES INFLAMMATIONS
  申请人：AVENTIS PHARMA INC

  公开号：WO2004100946A1

  公开（公告）日：2004-11-25

  The present invention provides compounds of Formula (I) Wherein ( ) is an optional ethylene bridge; R1 is alkyl, cycloalkyl, aryl or aryl substituted with one or more substituents selected from alkyl, alkoxy and amino, or R1 is pyridyl or pyridyl substituted with one or more substituents selected from alkyl, alkoxy and amino; R2 is optionally substituted alkyl, alkoxyalkyl, optionally substituted cycloalkylalkyl, arylalkyl, or R2 is arylalkyl substituted with one or more substituents selected from alkyl, alkoxy; X is -C(O)-, -C(O)-CH2-, -S(O)2-, or NH-C(O)- ; and A is optionally substituted alkyl or other substituents as defined in claim 1. Pharmaceutical compositions comprising such compounds, their preparation, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and/or tumor necrosis factor (TNF), such as asthma or joint inflammation.

  本发明提供了Formula (I)的化合物，其中( )是可选的乙烯桥；R1是烷基、环烷基、芳基或芳基，其上取代基可为烷基、烷氧基和氨基中的一种或多种，或者R1是吡啶基或吡啶基，其上取代基可为烷基、烷氧基和氨基中的一种或多种；R2是可选取代的烷基、烷氧基烷基、可选取代的环烷基烷基、芳基烷基，或者R2是芳基烷基，其上取代基可为烷基、烷氧基中的一种或多种；X是-C(O)-、-C(O)-CH2-、-S(O)2-或NH-C(O)-；A是可选取代的烷基或其他在权利要求1中定义的取代基。包括这些化合物的药物组合物、其制备以及在治疗能够通过抑制p38激酶和/或肿瘤坏死因子(TNF)调节的疾病状态中的药用，如哮喘或关节炎。
• Physiochemical Tuning of Potent<i>Escherichia coli</i>Anti-Adhesives by Microencapsulation and Methylene Homologation
  作者：Dimitri Alvarez Dorta、Thibaut Chalopin、Adeline Sivignon、Jérôme de Ruyck、Tetiana I. Dumych、Rostyslav O. Bilyy、David Deniaud、Nicolas Barnich、Julie Bouckaert、Sébastien G. Gouin

  DOI：10.1002/cmdc.201700061

  日期：2017.6.21

  trapped water molecule, and π-stacking with Tyr48 of FimH, respectively. Consequently, we developed NeoTazMan homologated with a methylene group for low-pH and mannosidase stability with a conserved NH group and bearing various heterocyclic aglycones. Microencapsulation of the lead NeoTazMan in γ-cyclodextrin dramatically improved water solubility without disrupting the affinity for FimH or the anti-adhesive

  噻唑基氨基甘露糖苷（TazMan）是FimH拮抗剂，具有对抗黏附性大肠杆菌（AIEC）促进克罗恩病患者肠道炎症的抗粘附能力。TazMan铅在体外具有很高的效力，但由于低pH稳定性和水溶性，其体内效率有限。我们最近开发了第二代稳定的TazMan，但抗粘连效果却低于第一代。在本文中，我们报道了FimH中的TazMan铅的共晶体结构，揭示了端粒的NH基团和第二噻唑部分与捕获的水分子提供了正的氢键相互作用，并与FimH的Tyr48形成了π堆积。所以，我们开发了与亚甲基同源的NeoTazMan，以降低pH和甘露糖苷酶的稳定性，并具有一个保守的NH基并带有各种杂环糖苷配基。领先的NeoTazMan微囊在γ-环糊精中的微囊化大大改善了水溶性，而不会破坏对FimH的亲和力或对克罗恩病患者分离出的AIEC的抗粘连作用。